SeraSeal, the world’s first and only primary hemostatic agent, has been approved for use in trauma and emergency bleed management under the Nammai Kaakkum 48 (NK-48) scheme of the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHiS) in Tamil Nadu.
This milestone approval will strengthen emergency care across 702 empanelled state hospitals, covering a wide range of specialties including neuro, ENT, spine, cardiac, vascular, liver, kidney transplant, and orthopaedic surgeries.
The NK-48 scheme, a crucial component of the Innuyir Kappom Thittam (IKT), provides cashless treatment for road accident victims within the first 48 hours. The initiative aims to reduce mortality rates and improve trauma care efficiency by ensuring access to immediate medical intervention.
SeraSeal, developed by US-based Wortham Labs, is a groundbreaking primary hemostatic agent engineered to stop bleeding on contact, making it a game-changer in emergency and surgical applications. Formulated with agar and bovine factor proteins (IIa, VIIa, IXa, and Xa), it acts as a catalyst in the clot formation process, delivering superior efficiency in controlling both arterial and venous hemorrhages. Unlike conventional hemostatic agents, SeraSeal is effective across all coagulopathies, including those induced by anticoagulant drugs and platelet inhibitors.
